Pharmaceuticals

This strategy represents a high-risk, high-reward portfolio. It bypasses traditional large pharmaceutical companies that rely on patent cliffs and stable cash flows, instead investing heavily in emerging biotech firms that own medicines in clinical trials and boast disruptive technologies. The returns from this strategy are driven not by stable drug sales, but by event-driven value re-evaluation resulting from successful clinical data, regulatory approvals, or the launch of blockbuster drugs.